Carboplatin/Paclitaxel +/-Gemcitabine in Treating Patients With Ovarian Epithelial or Fallopian Tube Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

1,742

Participants

Timeline

Start Date

August 31, 2002

Primary Completion Date

July 31, 2009

Study Completion Date

January 31, 2011

Conditions
Fallopian Tube CancerOvarian Cancer
Interventions
DRUG

TCG

DRUG

TC

Trial Locations (17)

30659

Frauenklinik der MHH, Hanover

39108

Universitaetsklinkum Magdeburg der Otto-von-Guericke-Universitaet Magdeburg, Magdeburg

75181

Hotel Dieu de Paris, Paris

DK2730

Herlev Hospital - University Hospital of Copenhagen, Copenhagen

D-28205

Zentralkrankenhaus, Bremen

DOH-40217

Evangelisches Krankenhaus, Düsseldorf

D-45122

Universitaetsklinikum Essen, Essen

D-65929

Staedtische Kliniken Frankfurt am Main - Hoechst, Frankfurt

D-76137

Vincentius Krankenhaus, Karlsruhe

D-24105

University Hospital Schleswig-Holstein - Kiel Campus, Kiel

D-81377

Klinikum Grosshadern der Ludwig-Maximilians Universitaet Muenchen, Munich

D-81675

Klinikum Rechts Der Isar - Technische Universitaet Muenchen, Munich

D-48129

Klinik und Poliklinik fuer Frauenheilkunde und Geburtshilfe - Universitaetsklinikum Muenster, Münster

D-72076

Universitaetsklinikum Tuebingen, Tübingen

D-89075

Universitaet Ulm, Ulm

D-65199

Dr. Horst-Schmidt-Kliniken, Wiesbaden

N-0310

Norwegian Radium Hospital, Oslo

All Listed Sponsors
collaborator

Nordic Society of Gynaecological Oncology - Clinical Trials Unit

OTHER

collaborator

GERCOR - Multidisciplinary Oncology Cooperative Group

OTHER

lead

AGO Study Group

OTHER

NCT00052468 - Carboplatin/Paclitaxel +/-Gemcitabine in Treating Patients With Ovarian Epithelial or Fallopian Tube Cancer | Biotech Hunter | Biotech Hunter